Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 7Breast Neoplasms 5Glioma 4Glioblastoma 4Neoplasms 3Gliosarcoma 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Esophageal Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Urethral Neoplasms 1Ureteral Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Thyroid cancer, medullary 1Thyroid Neoplasms 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Small Cell Lung Carcinoma 1Relapsed Pediatric Solid Tumor 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Precancerous Conditions 1Pleural Effusion 1Pheochromocytoma 1

Interventions

vandetanib 1sacubitril and valsartan sodium hydrate drug combination 1lenvatinib 1fluorodopa F 18 1cabozantinib 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Thyroid cancer, medullary × vandetanib × Clear all
NCT03630120 2021-07-14

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
6 enrolled 9 charts
EndocrineHead & Neck

Thyroid cancer, medullary, Thyroid Cancer, Papillary, Thyroid Diseases, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡